Quarterly ResultMay 14, 2026, 04:38 PM
Autolus Q1 Product Revenue $26.2M; Net Loss $(71.6)M
AI Summary
Autolus Therapeutics reported a significant increase in product revenue for the first quarter of 2026, reaching $26.2 million, primarily driven by the commercialization of AUCATZYL in the US and its recent launch in the UK. Despite the revenue growth, the company's net loss slightly widened to $(71.6) million. Autolus, a foreign private issuer, voluntarily filed this 10-Q and stated that its existing financial resources are sufficient to fund operations for at least one year, even with recurring losses and an accumulated deficit of $1.46 billion.
Key Highlights
- Product revenue, net, increased to $26.2 million for Q1 2026, up from $9.0 million in Q1 2025.
- Net loss for Q1 2026 was $(71.6) million, compared to $(70.2) million for Q1 2025.
- Basic and diluted net loss per ordinary share was $(0.27) for Q1 2026, versus $(0.26) for Q1 2025.
- Cash and cash equivalents stood at $130.9 million as of March 31, 2026.
- Net cash used in operating activities improved to $(65.3) million in Q1 2026 from $(75.6) million in Q1 2025.
- AUCATZYL launched in the United Kingdom in January 2026, following US launch in January 2025.
- The EU launch of AUCATZYL is currently on hold, with no EU product revenue anticipated in 2026.
- Management expects existing financial resources to fund operations for at least one year.
Price Impact
More from AUTL